N8 Medical Hires Industry Leader as Chief Operating Officer

N8 Medical, Inc. is pleased to announce that Michael Triplett, Ph.D. has joined the company as Chief Operating Officer.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Columbus, OH (PRWEB) October 09, 2012

N8 Medical, Inc., an emerging biomedical technology company focused on developing novel, proprietary antimicrobial coatings for medical devices and pharmaceuticals, is very pleased to announce that Michael Triplett, Ph.D. has agreed to join N8 Medical as Chief Operating Officer, effective October 8th, 2012.

Dr. Triplett comes to N8 from Battelle Memorial Institute, where he directed Strategic Marketing for the Health & Life Sciences Global Business. Previously at Battelle, Dr. Triplett directed strategic planning, business development and commercialization efforts in the Biopharmaceuticals, Medical Devices and Diagnostics business. He has a BS in Chemical Engineering and a Doctorate of Philosophy in Chemical Engineering, both from The Ohio State University. Before joining Battelle, he worked at both Procter & Gamble and Ventaira Pharmaceuticals in product development and pharmaceutical development capacities. He is an author of several publications, a noted speaker, and an inventor. Dr. Triplett will lead development efforts for N8’s various applications for its proprietary cationic selective antimicrobial (CSA) technology.

“I am excited to be joining an accomplished group of entrepreneurs with a proven track record of success in the medical device and pharmaceutical industries and even more excited about the possibility of improving patient health outcomes,” said Michael Triplett, “N8’s CSA technology presents significant opportunities to minimize the risk of infections associated with medical device usage and to treat traditional antibiotic resistant strains of bacterial infections.”

“We are very gratified that after a meaningful diligence period, Dr. Triplett decided to join the N8 team and lead our operations,” said David J. Richards, Chief Executive Officer of N8 Medical, “His experience and industry relationships will help assure N8’s success.”

N8 Medical recently announced a significant licensing transaction as well as highly favorable test results indicating that CSAs do not engender mutational resistance like traditional antibiotic drugs.

About N8 Medical, Inc.:
N8 Medical, Inc. is an emerging biomedical technology company focused on creating innovative medical devices and pharmaceuticals to effectively combat a broad spectrum of infectious diseases and other conditions, including those attributable to multidrug resistant bacteria and those that cause hospital acquired infections. N8 Medical’s core technology is a new class of patented, synthetic antimicrobial compounds known as CSAs. N8 Medical is a privately held entity, backed by private equity firm Empire Advisors, LLC, and is based in Columbus, Ohio with facilities at TechColumbus (http://www.techcolumbus.org).

For additional information please visit http://www.N8Medical.com


Contact

  • Contact
    N8 Medical
    877.686.3338 x27
    Email